Krisstina Gowin, D.O.

Krisstina Gowin, D.O.
Hematologist and Integrative Medicine
Clinical Expertise
  • Hematology
  • General Oncology
  • Integrative Medicine
Research Area
  • Myeloproliferative Neoplasms
  • Meditative Movement
  • Lifestyle Medicine
Academic Appointments
  • Education Director, Cherng Family Center for Integrative Oncology
  • Associate Clinical Professor, Medical Oncology and Therapeutics Research, Department of Supportive Care Medicine

Krisstina Gowin, D.O., leads education at City of Hope’s Cherng Family Center for Integrative Oncology, one of the first cancer center-based integrative medicine programs. With over 40 percent of cancer patients currently seeking integrative care, Dr. Gowin’s expertise in integrative therapies is vital to those interested in innovative approaches to support cancer treatment and healing.

“I want patients to know they are not alone in seeking these therapies and there are evidence-based resources to help them,” she says.

A hematologist/oncologist, Dr. Gowin is also an expert in myeloproliferative neoplasms (MPN), a rare blood cancer. She has authored numerous studies and Living Well with Myeloproliferative Neoplasm, a guide addressing an integrative and wellness-based approach to patient care.

Dr. Gowin completed her Hematology Oncology fellowship at the Mayo Clinic Arizona and her Integrative fellowship at Andrew Weil Center for Integrative Medicine at the University of Arizona, where she later directed the fellowship program. She completed a residency in internal medicine at the University of Southern California and medical training at Chicago College of Osteopathic Medicine.

Recognized for her commitment to whole-person healing, she has received awards such as the Humanism in Medicine Award.

Location

Education & Experience

Board Certifications
  • 2012 American Board of Internal Medicine Internal Medicine Certification
  • 2016 American Board of Internal Medicine Oncology Certification
  • 2016 Washington State Osteopathic Physician & Surgeon License
  • 2017 American Board of Internal Medicine Hematology Certification
  • 2017 Medical Board of California Physician & Surgeon A
  • 2018 Arizona Board of Osteopathic License
  • 2022 American Board of Physicians Specialties, Integrative Medicine Certification
Degrees
  • 2009, Doctor of Osteopathic Medicine, Chicago College of Osteopathic Medicine; Chicago, Illinois
  • 2005, Master of Arts, Molecular, Cellular, and Developmental Biology, University of California; Santa Barbara, California
  • 2003, Bachelor of Arts, Biological Science, University of California; Santa Barbara, California
Fellowships
  • 2015-2017, Integrative Medicine Fellowship, University of Arizona; Tucson, Arizona
  • 2012-2016, Hematology/Oncology Fellowship, Mayo Clinic; Scottsdale, Arizona
Residency
  • 2008-2012, Internal Medicine Residency, University of Southern California; Los Angeles, California
Professional Experience
  • 2024-present, Education Director, Cherng Family Center for Integrative; Oncology and Associate Clinical Professor, Medical Oncology and Therapeutics Research, City of Hope Orange County; Irvine, California
  • 2023-2024, Associate Professor of Medicine, Clinical Scholar, Division of Hematology/Oncology, University of Arizona Cancer Center; Tucson, Arizona
  • 2018-2023, Assistant Professor of Medicine, Clinical Scholar, Division of Hematology/Oncology, University of Arizona Cancer Center; Tucson, Arizona
  • 2016-2018, Staff Physician, Hematologist/Oncologist, Salish Integrative Cancer Center; Fife, Washington

Publications

  • Mahmud M, Vasireddy S, Gowin K, Amaraneni A. Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape. Int J Mol Sci. 2023 Dec 12;24(24):17383.
  • Okolo O, Wertheim BC, Larsen A, Sweeney NW, Ahlstrom JM, Gowin K. Integrative medicine in multiple myeloma and plasma cell disorders. Complement Ther Med. 2023 May;73:102939. doi: 10.1016/j.ctim.2023.102939. Epub 2023 Mar 2. PMID: 36868288.
  • Pandya SK, Pandya A, Larsen A, Gowin K. A Review of The Synergistic Effects of Curcumin with Proteasome Inhibitors in Multiple Myeloma Preclinical Models. Integrative Cancer Therapies. 2023;22. doi:10.1177/15347354231159322
  • Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD Jr, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC; DETERMINATION Investigators. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022 Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5.PMID: 35660812 Clinical Trial. PMID: 35660812, PMCID: PMC10040899, DOI: 10.1056/NEJMoa2204925
  • Jacinta Perram, David M. Ross, Donal McLornan, Krisstina Gowin, Nicolas Kröger, Vikas Gupta, Clinton Lewis, Nico Gagelmann, Nada Hamad. Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis. American Journal of Hematology, Volume 97, Issue 11, July 8, 2022 https://doi.org/10.1002/ajh.26654
  • Win H, Russell S, Wertheim BC, Maizes V, Crocker R, Brooks AJ, Mesa R, Huberty J, Geyer H, Eckert R, Larsen A, Gowin K. Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study. JMIR Form Res 2022;6(3):e33581. https://formative.jmir.org/2022/3/e33581 DOI: 10.2196/33581
  • Gowin K. TIMING IS EVERYTHING: When IS the Time Right for Transplant n Myelofibrosis Therapy? American Society for Transplant and Cellular Therapy 28 (2022) 177-178.
  • Okolo O, Wertheim BC, Larsen A, Sweeney NW, Gowin KL. Integrative medicine and plasma cell disorders. Journal of Clinical Oncology. 2021;39(15_suppl):e20044-e20044
  • Gowin K, Skerget S, Keats JJ, Mikhael J, Cowan AJ. Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment. PMID:34425325, DOI:10.1016/j.leukres.2021.106687
  • Yousif, A., Cui, H., Russell, S., Larsen, A., and Gowin, K. Risk of infection associated with daratumumab treatment for Multiple Myeloma. American Journal of Hematology, Volume 95, Issues s1, p. s3-s38 15Oct2020 P-39 https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.26005
  • Gowin, K., Langlais, B., Kosiorek, H., Dueck, A. C., Millstine, D., Huberty, J., Eckert, R., and Mesa, R. The SIMM Study: Survey of Integrative Medicine in Myeloproliferative Neoplasms. Cancer Medicine. 2020. September 30.
  • Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V. Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances. 2020. 4(9): 1965–1973. May 8. https://doi.org/10.1182/bloodadvances.2019001084